The incidence of bleomycin induced lung toxicity is increased in Hodgkin lymphoma patients over 45 years exposed to granulocyte-colony stimulating growth factor-Reference-Cited by-同舟云学术

The incidence of bleomycin induced lung toxicity is increased in Hodgkin lymphoma patients over 45 years exposed to granulocyte-colony stimulating growth factor

Published:2018-10-02 Issue:4 Volume:60 Page:927-933
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Andersen Maja D.¹,Kamper Peter¹,d’Amore Alexander¹,Clausen Michael¹,Bentzen Hans¹,d'Amore Francesco¹

Affiliation:

1. Department of Haematology, Aarhus University Hospital, Aarhus C, Denmark

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/10428194.2018.1515939

Reference36 articles.

1. Randomized Comparison of ABVD and MOPP/ABV Hybrid for the Treatment of Advanced Hodgkin’s Disease: Report of an Intergroup Trial

2. The pathogenesis of bleomycin-induced lung injury in animals and its applicability to human idiopathic pulmonary fibrosis

3. The pathogenesis of pulmonary fibrosis: Is there a fibrosis gene?

4. Effect of ABVD chemotherapy with and without mantle or mediastinal irradiation on pulmonary function and symptoms in early-stage Hodgkin's disease.

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mechanisms of Bleomycin-induced Lung Fibrosis: A Review of Therapeutic Targets and Approaches;Cell Biochemistry and Biophysics;2024-07-02

2. Pulmonary diseases in patients with classical Hodgkin lymphoma relative to a matched background population: A Danish national cohort study;British Journal of Haematology;2024-04-29

3. Drug-induced interstitial lung disease: a narrative review of a clinical conundrum;Expert Review of Respiratory Medicine;2024-02

4. Unfavorable early-stage Hodgkin lymphoma: assessment of patient characteristics in a real-world setting;Future Oncology;2023-06

5. Older patients with Hodgkin Lymphoma: Walking the tightrope of efficacy and toxicity;Frontiers in Oncology;2023-01-13